Role of and polymorphisms in different outcomes upon Hepatitis B virus infection and prognosis to lamivudine therapy.

, having been found expressing differently in liver tissues in our previous work, including and , which are structural homologs named and Recent studies have indicated that involved in the development and proliferation of HepG2 cell, and may be associated with tumor susceptibility. Based on this, we tested the effects of and single-nucleotide polymorphisms for all major Hepatitis B virus (HBV) outcomes and lamivudine (LAM) treatment in Han Chinese. A total of 1649 samples were enrolled, and peripheral blood samples were collected in the present study. The single-nucleotide polymorphisms in the and region were genotyped using MALDI-TOF MS. Our study demonstrated there was no obvious relevance of either -rs33635 or -rs974285 polymorphisms with HBV susceptibility, spontaneous recovery, and development of HBV-related diseases. However, we showed for the first time to our knowledge that -rs33635C was a predictor for LAM therapy (viral response: odds ratio (OR) = 2.436, =0.022; biochemical response: OR = 3.328, =1.73 × 10). These findings might provide potential implications for therapeutic guidance.